Drug Detail

Information about onalespib

Generic Name	onalespib
IND	AT13387
Brand Name (US)
Manufacturer	Astex Therapeutics, Ltd.
Drug Type	HSP90 Inhibitor
Delivery	Intravenous
Approval Status	Phase 1
Indications	Solid Tumors
Overall Strategy	KIT Protein Based
Strategy	Destroy KIT
Drug Category	HSP90 inhibitor

AT13387 is a potent small molecule inhibitor of Heat Shock Protein 90 (HSP90). HSP90 inhibitors have shown good activity in the test tube against Gleevec-resistant cell lines. It remains to be seen how effective HSP90 inhibitors will be in GIST patients, although they have shown activity in phase I/II trials for a different drug.
In the phase I trial, one GIST patient had a response and stable disease for 10 months. 7 of 62 patients (all solid tumor cancer types) had stable disease for >120 days. See link with trial results.